AU2001247929A1 - Inhibition of thrombosis by treatment with p-selectin antagonists - Google Patents

Inhibition of thrombosis by treatment with p-selectin antagonists

Info

Publication number
AU2001247929A1
AU2001247929A1 AU2001247929A AU4792901A AU2001247929A1 AU 2001247929 A1 AU2001247929 A1 AU 2001247929A1 AU 2001247929 A AU2001247929 A AU 2001247929A AU 4792901 A AU4792901 A AU 4792901A AU 2001247929 A1 AU2001247929 A1 AU 2001247929A1
Authority
AU
Australia
Prior art keywords
psgl
protein
selectin
amino acid
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247929A
Other languages
English (en)
Inventor
Michael J. Eppihimer
Alan S. Harris
Robert G. Schaub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of AU2001247929A1 publication Critical patent/AU2001247929A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001247929A 2000-03-31 2001-04-02 Inhibition of thrombosis by treatment with p-selectin antagonists Abandoned AU2001247929A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19378700P 2000-03-31 2000-03-31
US60193787 2000-03-31
PCT/US2001/010622 WO2001075107A2 (en) 2000-03-31 2001-04-02 Use of p-selectin glycoprotein ligand-1 (psgl-1) and fragments thereof for the inhibition of thrombosis

Publications (1)

Publication Number Publication Date
AU2001247929A1 true AU2001247929A1 (en) 2001-10-15

Family

ID=22715003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247929A Abandoned AU2001247929A1 (en) 2000-03-31 2001-04-02 Inhibition of thrombosis by treatment with p-selectin antagonists

Country Status (7)

Country Link
US (1) US20030166521A1 (de)
EP (2) EP1268786A2 (de)
JP (1) JP2003529610A (de)
AU (1) AU2001247929A1 (de)
CA (1) CA2404572A1 (de)
NZ (1) NZ521687A (de)
WO (1) WO2001075107A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022820A1 (en) * 2000-09-12 2002-03-21 Genetics Institute, Llc Inhibition of stenosis or restenosis by p-selectin antagonists
CN1561225A (zh) * 2001-08-03 2005-01-05 遗传研究所公司 缺血后白细胞－内皮细胞相互作用的调节
AU2003233008B2 (en) * 2002-04-22 2008-04-24 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
US7807636B1 (en) 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
AU2008242757A1 (en) * 2007-04-20 2008-10-30 Oregon Health & Science University Ultrasound imaging with targeted microbubbles
DK2603242T3 (en) 2010-08-09 2018-06-18 Bracco Suisse Sa TARGETED GAS FILLED MICROVESICLES
US9770411B2 (en) 2010-12-24 2017-09-26 Bracco Suisse S.A. Methods of using gas-filled microvesicles covalently bound to an antigen
US8889628B2 (en) 2011-11-28 2014-11-18 Gray D Shaw Soluble tandem selectin glycoprotein ligand molecules
US11370826B2 (en) * 2016-02-09 2022-06-28 Bracco Suisse Sa Recombinant chimeric protein for selectins targeting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
EP0698031A4 (de) * 1993-05-14 1997-07-09 Cytel Corp SIALYL LEx ANALOGE ALS INHIBITOREN ZELLULÄRER ADHÄSION
US20020040008A1 (en) * 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
CA2247115C (en) * 1996-03-01 2008-11-18 The Regents Of The University Of California Inhibition of selectin binding

Also Published As

Publication number Publication date
NZ521687A (en) 2004-11-26
WO2001075107A3 (en) 2002-04-11
WO2001075107A2 (en) 2001-10-11
EP1518931A1 (de) 2005-03-30
JP2003529610A (ja) 2003-10-07
EP1268786A2 (de) 2003-01-02
US20030166521A1 (en) 2003-09-04
CA2404572A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
US20020177151A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
WO2002022820A1 (en) Inhibition of stenosis or restenosis by p-selectin antagonists
US20030092041A1 (en) Novel use for muscarinic receptor M5 in the diagnosis and treatment of metabolic disorders
EP1518931A1 (de) Verwendung von PSGL-1 (P-Selectin glycoprotein ligand 1) und dessen Fragment zur Hemmung von Thrombose
US20040157253A1 (en) Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
US20060142187A1 (en) Methods for modulating cell-to-cell adhesion using an agonist of C1INH-type protein activity
US20050288218A1 (en) Methods for treating and preventing sepsis using modified C1 inhibitor or fragments thereof
WO2002012887A2 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
US20040086519A1 (en) Inhibition of stenosis or restenosis by P-selectin ligand antagonists
US20060148002A1 (en) Methods and compositions for the treatment and diagnosis of body weight disorders
US20030212016A1 (en) Methods and compositions for the treatment and diagnosis of body weight disorders
AU2007203133A1 (en) Inhibition of Thrombosis by Treatment with P-Selectin Antagonists
WO2003013575A1 (en) Modulation of leukocyte-endothelial interactions following ischemia
US7459523B2 (en) Equine P-selectin glycoprotein ligand-1 and uses thereof
US20040077001A1 (en) Use for carboxypeptidase-A4 in the diagnosis and treatment of metabolic disorders
AU2002317576A1 (en) Modulation of leukocyte-endothelial interactions following ischemia
WO2004000999A2 (en) Identification of a receptor controlling migration and metastasis of skin cancer cells
WO2008063147A2 (en) Anthrax polypeptide binding
US6953778B2 (en) Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
US20060211042A1 (en) Methods of identifying modulators of cellular glycosylation using gtrap3-18
US20030091573A1 (en) Methods and compositions for the diagnosis and treatment of hematological disorders using 16319
WO2002090576A1 (en) Methods and compositions for the treatment and diagnosis of body weight disorders
JP2005535313A (ja) オステオポンチン、オリゴデンドロサイトおよび髄鞘形成

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted